

April 30, 2026

<p>To</p> <p>The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001</p> <p>Code: 540222</p>	<p>To</p> <p>The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051</p> <p>Code: LAURUSLABS</p>
--	--

Dear Sir / Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

We would like to inform that the Board of Directors of the Company at their meeting held on April 30, 2026, has *inter alia* transacted and approved the investment of an amount up to INR equivalent of EURO 9,800,000/- (Euro Nine Million Eight Hundred Thousand only) in KRKA Pharma Private Limited, a joint venture of the Company.

Further, KRKA d.d., Novo mesto, Slovenia (co-venturer) shall also invest an amount of INR equivalent of about EURO 10,200,000/- (Euro Ten Million and Two Hundred Thousand only) in KRKA. The existing shareholding ratio of 51:49 between KRKA d.d., Novo mesto and Laurus Labs Limited, respectively, shall continue to remain the same after the above investment.

This additional investment in KRKA aligns with the Company's strategic growth plans and long-term business objectives, and the fund will be utilised by KRKA to meet its capex plan for setting up of a manufacturing facility.

The relevant details as required under the SEBI Listing Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is annexed herewith as **Annexure**.

The Board Meeting commenced at 02.00 p.m. and concluded at 03.00 p.m.

This is for your information and records.

Thanking you,s

Yours sincerely,
For **Laurus Labs Limited**

G. Venkateswar Reddy
Company Secretary & Compliance Officer

Encl: A/a

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E, Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **F** +91 891 682 1103

E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

(Pursuant to SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026)

Further Investment in KRKA Pharma Private Limited

a	Name of the target entity, details in brief such as size, turnover etc.	KRKA Pharma Private Limited (“KRKA”), a joint venture of the Company, incorporated under the Companies Act, 2013. The Authorised Share Capital of KRKA is INR 370,00,00,000/- divided into 37,00,00,000 equity shares of INR 10/- each and paid-up Share Capital of the Company is INR 315,00,00,000/- divided into 31,50,00,000 equity shares of INR 10/- each. Turnover: 2025-26 – INR 10.47 million
b	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”	Yes. KRKA is the joint venture of the Company having few common Directors. The proposed investment in KRKA by the Company would fall within the purview of related party transaction in terms of SEBI Listing Regulations. The nature of interest is to the extent of investment by the Company and the transaction is being done at arms' length basis. No Promoter/ Promoter Group/ other Group Company is holding equity shares or any interest in the target entity.
c	Industry to which the entity being acquired belongs	KRKA belongs to the pharmaceutical industry.
d	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	KRKA is already a joint venture company of our Company and further investment by the Company and by KRKA d.d., Novo mesto, Slovenia (“co-venturer”) will enable KRKA to meet its capex plan for setting up of a manufacturing facility.
e	Brief details of any governmental or regulatory approvals required for the acquisition	No approvals required.
f	Indicative time period for completion of the acquisition	The investment by the Company is expected to be completed during the financial year 2026-27.
g	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration by way of subscribing to Equity Shares which shall be issued by KRKA to the Company.
h	Cost of acquisition and/or the price at which the shares are acquired	Cost of acquisition: An amount of INR equivalent of Up to EURO 9,800,000/- (Euro Nine Million and Eight Hundred Thousand only) Price at which the shares are acquired: INR 10/- each per equity share (Face Value) on Rights Issue basis.
i	Percentage of shareholding / control acquired and / or number of shares acquired	The current percentage of shareholding in the target entity is 49% and after this investment by our Company and the co-venturer, the percentage of shareholding by the Company shall remain same at 49%.
j	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Brief background: KRKA was incorporated in April, 2024 and is yet to commence its business operations but however the Company is currently rendering R&D services. Date of Incorporation: April 12, 2024 Country in which the acquired entity has presence: India Turnover for the last three years: 2023-24 – Not Applicable 2024-25 – Nil 2025-26 – INR 10.47 million

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, F +91 891 682 1103

E info@lauruslabs.com, W lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518